
Release date: 2025-03-07 11:51:39 Article From: Lucius Laos Recommended: 285
Osimertinib is an important drug for the treatment of non-small cell lung cancer, and understanding its side effects is crucial for patients and doctors.
During the use of osimertinib, patients may experience a series of side effects that not only affect the patient's quality of daily life, but also pose challenges to the choice of treatment options.
One of the most common side effects after taking osimertinib is the rash, which occurs in about 34%-43% of patients with varying severity. In addition, dry skin is also a common adverse reaction, occurring in between 20% and 30%. Patients should take care of skin moisturization and avoid direct sunlight in their daily life to reduce the effects of these symptoms.
Diarrhoea is also a commonly reported problem among osimertinib users, with an incidence ranging from 33% to 47%. Mild diarrhoea can be relieved by adjusting dietary habits, while severe cases require medical intervention. Maintaining a light diet and avoiding greasy foods can help reduce the burden on the stomach.
According to the study, 4.4% of patients treated with osimertinib may develop cardiac insufficiency related to cancer treatment. Although this percentage is relatively small, it is a cause for concern, especially in patients with a history of heart disease.
In the face of the side effects of osimertinib, appropriate management measures can significantly improve the quality of life of patients.
When a rash or dry skin occurs, patients should choose gentle, non-irritating cleaners and regularly use moisturizers to keep their skin moisturized. If symptoms continue to worsen, you should seek medical attention to adjust your treatment plan.
To cope with diarrhoea, patients are advised to increase their dietary fiber intake and maintain adequate hydration. At the same time, antidiarrheal medications can be used to control symptoms when appropriate, as prescribed.
Regularly monitor cardiac function indicators, and consult a professional physician if abnormalities are found. For individuals with risk factors for cardiovascular disease, it is even more important to pay close attention to changes in physical conditions.
With a better understanding of the common side effects of osimertinib and strategies for managing them, patients are better able to work with their physicians to develop a personalized treatment plan that improves quality of life and is better supported on their cancer journey. Proper identification and management of these side effects will not only help patients maintain good physical condition, but also increase their confidence in fighting the disease.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3522025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3262025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3012025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643